Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
Steady M&A Deals To Begin 2025, Disappointing IPOs So Far
A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.
Eli Lilly Taps High-Grade Market to Fund Cancer Drug Purchase
Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...
International Financing Review20h
IFR SNAPSHOT - HY primary continues borrowing run
The asset-backed primary is bracing for another busy week after 16 issuers priced more than US$14.8bn last week, while the RMBS sector is expecting a number of jumbo deals. Over in the ECM, primary ...
MarketWatch21h
Sarepta Therapeutics Inc.
Dyne Therapeutics Inc.-5.60% $1.56B ...